The future holds great potential for psychedelics as therapeutic treatment options for children and adolescents, but not without a careful assessment of risks. But even now, adolescents are legally using prescribed substances such as ketamine to address treatment resistant depression. If and when MDMA becomes a legally-apporved medicine, the FDA will require additional testing in adolescent populations. And historically, children have ingested age-appropriate doses of plant medicines in ceremonial contexts within indigenous communities. Plant Parenthood will explore these topics in depth with our expert panel and invite questions from our community.

We are pleased to welcome our expert panelists: Marlena Robbins, Indigenous and Community Affairs Officer at the Chacruna Institute for Psychedelic Plant Medicines; Dr. Corine de Boer, Chief Medical Officer at MAPS Public Benefit Corporation; and Dr. Michael Bloch, Co-Director and Co-Founder of the Pediatric Depression Clinic at the Yale School of Medicine.